Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea FDA Prepares Guidelines On Phase 0 Clinical Trials To Draw More Early-stage Trials

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Korea FDA is gearing up to release guidelines on Phase 0 clinical trials in the first half of next year under its broader ambition to draw more early-stage clinical trials to the country

You may also be interested in...

Korea’s Drive To Shorten IND Approval Times Focuses On Early-stage Trials

KFDA is focusing on early-stage trials in a campaign to shorten IND approval times and draw more clinical trials to Korea

South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub

Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.

Korea FDA To Consider Substantial Reduction To IND Timeframe

As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts